User profiles for Roch Houot
Roch HOUOTProfessor of Hematology, University of Rennes Verified email at chu-rennes.fr Cited by 2034 |
[HTML][HTML] KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma
Background Patients with relapsed or refractory mantle-cell lymphoma who have disease
progression during or after the receipt of Bruton’s tyrosine kinase (BTK) inhibitor therapy have …
progression during or after the receipt of Bruton’s tyrosine kinase (BTK) inhibitor therapy have …
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
…, F Milletti, JM Rossi, R Vezan, BK Masouleh, R Houot - The Lancet, 2021 - thelancet.com
Background Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT)
consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute …
consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute …
[HTML][HTML] A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
…, E Gat, F Broussais, C Thieblemont, R Houot… - Nature medicine, 2022 - nature.com
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …
[HTML][HTML] Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma
…, C Haioun, H Maisonneuve, R Houot… - … England Journal of …, 2017 - Mass Medical Soc
Background Mantle-cell lymphoma is generally incurable. Despite high rates of complete
response after initial immunochemotherapy followed by autologous stem-cell transplantation, …
response after initial immunochemotherapy followed by autologous stem-cell transplantation, …
[HTML][HTML] Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study
…, R Khanal, MS Topp, R Houot… - Journal of clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell …
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell …
[HTML][HTML] Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
HE Kohrt, R Houot, K Weiskopf… - The Journal of …, 2012 - Am Soc Clin Investig
Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2;
also known as HER-2/neu), is indicated for the treatment of women with either early …
also known as HER-2/neu), is indicated for the treatment of women with either early …
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
HE Kohrt, R Houot, MJ Goldstein… - Blood, The Journal …, 2011 - ashpublications.org
Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural
killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 …
killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 …
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
…, A Avigdor, AS Halwani, R Houot… - Blood, The Journal …, 2017 - ashpublications.org
Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly
tested in patients with advanced lymphoma. Following treatment, many of those patients are …
tested in patients with advanced lymphoma. Following treatment, many of those patients are …
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
…, H Demarquette, E Boyle, R Houot… - Blood, The Journal …, 2017 - ashpublications.org
Allogeneic hematopoietic cell transplantation (allo-HCT) is indicated for patients with
relapsed or refractory Hodgkin lymphoma (HL). Although long-term disease control can be …
relapsed or refractory Hodgkin lymphoma (HL). Although long-term disease control can be …
[HTML][HTML] Born to survive: how cancer cells resist CAR T cell therapy
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …